Global Scans · Pharmaceuticals · Weekly Summary

• [New] By 2030, 80% of pharmaceutical companies are projected to partner with TechBios, leveraging agentic AI and quantum computing to reduce R&D costs and failure rates. IDC
• [New] The FDA's 2026 update to its biosimilar Q & A guidance will further facilitate biosimilar development in the U.S. Skadden, Arps, Slate, Meagher & Flom LLP
• [New] The cumulative effect is a streamlined clinical data package for biosimilar applications, which the FDA estimates could save developers up to 50% of PK study costs - potentially as much as $20 million per program - by avoiding unnecessary bridging studies. Skadden, Arps, Slate, Meagher & Flom LLP
• [New] With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability. Oncology Practice Management
• [New] Pharmaceutical manufacturers may need to balance partnerships with Chinese innovators against rising supply chain and security risks, while also absorbing a greater share of early-stage research and innovation costs to sustain global competitiveness. PwC
• [New] Leading Drug Therapy: Antipsychotic drugs are projected to dominate due to their established clinical efficacy, widespread adoption, and functional integration across pediatric and adolescent care settings, holding approximately 42% share in 2026. Persistence Market Research
• [New] Without urgent action, the WHO warns, drug-resistant infections could claim 39 million lives worldwide by 2050 and impose an annual economic burden of up to $412bn (£307bn). The Guardian
• [New] The approaching patent cliff-projected to expose as much as $300 billion in annual drug sales to loss of exclusivity by 2032 - is expected to keep pharmaceutical M&A activity active in 2026, but not necessarily drive a dramatic year-over-year spike in deal volume or size. Pharmaceutical Commerce
• [New] Investigational New Drug - enabling studies are expected to begin in H1 2026. GlobeNewswire
• [New] The latest change could cut $20 million from the cost of developing a biosimilar drug, potentially lowering the end price for consumers. American Chemical Society
• [New] The Patent Cliff: Between 2026 and 2030, Pfizer will lose exclusivity on drugs representing roughly $17 billion in annual revenue, including the blockbuster blood thinner Eliquis and the cancer drug Ibrance. The Chronicle-Journal
• [New] Long-term value: McKinsey estimates potential economic value from quantum computing applications in life sciences and drug discovery alone of $200 billion to $500 billion by 2035. Trantorinc
• [New] More individuals are enrolled in Medicare Advantage plans offering drug coverage compared to stand-alone prescription drug plans. ElderVoice
• [New] The global pharmaceutical industry is projected to surpass $1.8 trillion by 2026, driven by innovation, ageing populations, and expanding healthcare access. LinkedIn
• Diet changes linked to GLP-1 drug use could reach upwards of $12 billion snack sales lost over the next decade. FoodNavigator-USA.com
• Premium pharmaceutical-grade fish oil with high EPA and DHA concentration is expected to witness robust demand growth. openpr
• Sweden's nationwide PGx implementation could prevent adverse drug events annually. Market Data Forecast

Last updated: 24 March 2026